Randomized	O
Controlled	O
Trial	O
of	O
Mineralocorticoid	B:C0066563
Receptor	I:C0066563
Blockade	O
in	O
Children	O
with	O
Chronic	O
Kidney	I:C0403592
Allograft	I:C0403592
Nephropathy	I:C0403592
.	O

Randomized	O
Controlled	O
Trial	O
of	O
Mineralocorticoid	O
Receptor	I:C0066563
Blockade	B:C3540676
in	O
Children	O
with	O
Chronic	O
Kidney	I:C0403592
Allograft	I:C0403592
Nephropathy	I:C0403592
.	O

Randomized	O
Controlled	O
Trial	O
of	O
Mineralocorticoid	O
Receptor	I:C0066563
Blockade	O
in	O
Children	O
with	O
Chronic	B:C0403592
Kidney	I:C0403592
Allograft	I:C0403592
Nephropathy	I:C0403592
.	O

We	O
showed	O
that	O
mineralocorticoid	B:C0066563
receptor	I:C0066563
blockade	O
(	O
MRB	O
)	I:C3540676
prevented	O
acute	O
and	O
chronic	O
cyclosporine	I:C3875332
nephropathy	I:C3875332
(	O
CsA	O
-	I:C3875332
Nx	I:C3875332
)	O
in	O
the	O
rat	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	I:C0066563
blockade	B:C3540676
(	O
MRB	O
)	I:C3540676
prevented	O
acute	O
and	O
chronic	O
cyclosporine	I:C3875332
nephropathy	I:C3875332
(	O
CsA	O
-	I:C3875332
Nx	I:C3875332
)	O
in	O
the	O
rat	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	I:C0066563
blockade	O
(	O
MRB	B:C3540676
)	I:C3540676
prevented	O
acute	O
and	O
chronic	O
cyclosporine	I:C3875332
nephropathy	I:C3875332
(	O
CsA	O
-	I:C3875332
Nx	I:C3875332
)	O
in	O
the	O
rat	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	I:C0066563
blockade	O
(	O
MRB	O
)	I:C3540676
prevented	O
acute	O
and	O
chronic	B:C3875332
cyclosporine	I:C3875332
nephropathy	I:C3875332
(	O
CsA	O
-	I:C3875332
Nx	I:C3875332
)	O
in	O
the	O
rat	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	I:C0066563
blockade	O
(	O
MRB	O
)	I:C3540676
prevented	O
acute	O
and	O
chronic	O
cyclosporine	I:C3875332
nephropathy	I:C3875332
(	O
CsA	B:C3875332
-	I:C3875332
Nx	I:C3875332
)	O
in	O
the	O
rat	O
.	O

We	O
showed	O
that	O
mineralocorticoid	O
receptor	I:C0066563
blockade	O
(	O
MRB	O
)	I:C3540676
prevented	O
acute	O
and	O
chronic	O
cyclosporine	I:C3875332
nephropathy	I:C3875332
(	O
CsA	O
-	I:C3875332
Nx	I:C3875332
)	O
in	O
the	O
rat	B:C0034693
.	O

The	O
aim	O
of	O
this	O
translational	B:C3494163
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	O
administration	O
on	O
renal	O
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	B:C0961485
administration	O
on	O
renal	O
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	O
administration	B:C1533734
on	O
renal	O
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	O
administration	O
on	O
renal	B:C0564454
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	O
administration	O
on	O
renal	O
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	B:C0005558
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	O
administration	O
on	O
renal	O
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	O
-	O
proven	O
chronic	B:C0403592
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

The	O
aim	O
of	O
this	O
translational	O
study	I:C3494163
was	O
to	O
investigate	O
the	O
effect	O
of	O
long	O
-	O
term	O
eplerenone	O
administration	O
on	O
renal	O
allograft	I:C0564454
function	O
in	O
children	O
with	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
(	O
chronic	B:C0403592
allograft	I:C0403592
nephropathy	I:C0403592
)	O
.	O

Renal	B:C0022671
transplant	I:C0022671
children	O
<	O
18	O
years	O
,	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
,	O
and	O
a	O
GFR	O
>	O
40	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
were	O
included	O
.	O

Renal	O
transplant	I:C0022671
children	O
<	O
18	O
years	O
,	O
biopsy	B:C0005558
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
,	O
and	O
a	O
GFR	O
>	O
40	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
were	O
included	O
.	O

Renal	O
transplant	I:C0022671
children	O
<	O
18	O
years	O
,	O
biopsy	O
-	O
proven	O
chronic	B:C0403592
allograft	I:C0403592
nephropathy	I:C0403592
,	O
and	O
a	O
GFR	O
>	O
40	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
were	O
included	O
.	O

Renal	O
transplant	I:C0022671
children	O
<	O
18	O
years	O
,	O
biopsy	O
-	O
proven	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
,	O
and	O
a	O
GFR	B:C0017654
>	O
40	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
were	O
included	O
.	O

Patients	O
with	O
BK	B:C0005670
virus	I:C0005670
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	I:C0022658
,	O
GFR	O
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	I:C0332293
calcium	O
antagonists	I:C0006684
or	O
antifungal	O
drugs	I:C0003308
were	O
excluded	O
.	O

Patients	O
with	O
BK	O
virus	I:C0005670
active	O
nephritis	B:C0027697
,	O
recurrence	O
of	O
renal	O
disease	I:C0022658
,	O
GFR	O
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	I:C0332293
calcium	O
antagonists	I:C0006684
or	O
antifungal	O
drugs	I:C0003308
were	O
excluded	O
.	O

Patients	O
with	O
BK	O
virus	I:C0005670
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	B:C0022658
disease	I:C0022658
,	O
GFR	O
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	I:C0332293
calcium	O
antagonists	I:C0006684
or	O
antifungal	O
drugs	I:C0003308
were	O
excluded	O
.	O

Patients	O
with	O
BK	O
virus	I:C0005670
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	I:C0022658
,	O
GFR	B:C0853068
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	I:C0332293
calcium	O
antagonists	I:C0006684
or	O
antifungal	O
drugs	I:C0003308
were	O
excluded	O
.	O

Patients	O
with	O
BK	O
virus	I:C0005670
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	I:C0022658
,	O
GFR	O
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	B:C0332293
with	I:C0332293
calcium	O
antagonists	I:C0006684
or	O
antifungal	O
drugs	I:C0003308
were	O
excluded	O
.	O

Patients	O
with	O
BK	O
virus	I:C0005670
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	I:C0022658
,	O
GFR	O
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	I:C0332293
calcium	B:C0006684
antagonists	I:C0006684
or	O
antifungal	O
drugs	I:C0003308
were	O
excluded	O
.	O

Patients	O
with	O
BK	O
virus	I:C0005670
active	O
nephritis	O
,	O
recurrence	O
of	O
renal	O
disease	I:C0022658
,	O
GFR	O
decline	I:C0853068
in	O
previous	O
3	O
months	O
,	O
or	O
treated	O
with	I:C0332293
calcium	O
antagonists	I:C0006684
or	O
antifungal	B:C0003308
drugs	I:C0003308
were	O
excluded	O
.	O

They	O
were	O
randomized	O
to	O
receive	O
placebo	B:C0032042
(	O
n=10	O
)	O
or	O
eplerenone	O
25	O
mg/d	O
for	O
24	O
months	O
(	O
n=13	O
)	O
.	O

They	O
were	O
randomized	O
to	O
receive	O
placebo	O
(	O
n=10	O
)	O
or	O
eplerenone	B:C0961485
25	O
mg/d	O
for	O
24	O
months	O
(	O
n=13	O
)	O
.	O

At	O
each	O
period	O
,	O
a	O
complete	O
clinical	O
examination	O
was	O
performed	O
and	O
blood	B:C0178913
and	O
urine	O
samples	I:C1610733
were	O
taken	O
.	O

At	O
each	O
period	O
,	O
a	O
complete	O
clinical	O
examination	O
was	O
performed	O
and	O
blood	O
and	O
urine	B:C1610733
samples	I:C1610733
were	O
taken	O
.	O

Urine	B:C1318439
creatinine	I:C1318439
,	O
8	O
-	I:C0050092
hydroxylated	I:C0050092
-	I:C0050092
guanosine	I:C0050092
,	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
(	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
)	O
,	O
and	O
kidney	O
injury	I:C2681921
molecule	I:C2681921
(	I:C2681921
KIM	I:C2681921
-	I:C2681921
1	I:C2681921
)	I:C2681921
levels	I:C2681921
were	O
also	O
assessed	O
.	O

Urine	O
creatinine	I:C1318439
,	O
8	B:C0050092
-	I:C0050092
hydroxylated	I:C0050092
-	I:C0050092
guanosine	I:C0050092
,	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
(	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
)	O
,	O
and	O
kidney	O
injury	I:C2681921
molecule	I:C2681921
(	I:C2681921
KIM	I:C2681921
-	I:C2681921
1	I:C2681921
)	I:C2681921
levels	I:C2681921
were	O
also	O
assessed	O
.	O

Urine	O
creatinine	I:C1318439
,	O
8	O
-	I:C0050092
hydroxylated	I:C0050092
-	I:C0050092
guanosine	I:C0050092
,	O
heat	B:C0256926
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
(	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
)	O
,	O
and	O
kidney	O
injury	I:C2681921
molecule	I:C2681921
(	I:C2681921
KIM	I:C2681921
-	I:C2681921
1	I:C2681921
)	I:C2681921
levels	I:C2681921
were	O
also	O
assessed	O
.	O

Urine	O
creatinine	I:C1318439
,	O
8	O
-	I:C0050092
hydroxylated	I:C0050092
-	I:C0050092
guanosine	I:C0050092
,	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
(	O
heat	B:C0256926
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
)	O
,	O
and	O
kidney	O
injury	I:C2681921
molecule	I:C2681921
(	I:C2681921
KIM	I:C2681921
-	I:C2681921
1	I:C2681921
)	I:C2681921
levels	I:C2681921
were	O
also	O
assessed	O
.	O

Urine	O
creatinine	I:C1318439
,	O
8	O
-	I:C0050092
hydroxylated	I:C0050092
-	I:C0050092
guanosine	I:C0050092
,	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
(	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
)	O
,	O
and	O
kidney	B:C2681921
injury	I:C2681921
molecule	I:C2681921
(	I:C2681921
KIM	I:C2681921
-	I:C2681921
1	I:C2681921
)	I:C2681921
levels	I:C2681921
were	O
also	O
assessed	O
.	O

In	O
kidney	B:C0586763
biopsy	I:C0586763
samples	I:C0586763
,	O
the	O
tubulo	O
-	I:C4285457
interstitial	I:C4285457
area	I:C4285457
affected	I:C4285457
by	I:C4285457
fibrosis	I:C4285457
(	O
TIF	O
)	O
and	O
glomerulosclerosis	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
24	O
months	O
.	O

In	O
kidney	O
biopsy	I:C0586763
samples	I:C0586763
,	O
the	O
tubulo	B:C4285457
-	I:C4285457
interstitial	I:C4285457
area	I:C4285457
affected	I:C4285457
by	I:C4285457
fibrosis	I:C4285457
(	O
TIF	O
)	O
and	O
glomerulosclerosis	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
24	O
months	O
.	O

In	O
kidney	O
biopsy	I:C0586763
samples	I:C0586763
,	O
the	O
tubulo	O
-	I:C4285457
interstitial	I:C4285457
area	I:C4285457
affected	I:C4285457
by	I:C4285457
fibrosis	I:C4285457
(	O
TIF	B:C4285457
)	O
and	O
glomerulosclerosis	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
24	O
months	O
.	O

In	O
kidney	O
biopsy	I:C0586763
samples	I:C0586763
,	O
the	O
tubulo	O
-	I:C4285457
interstitial	I:C4285457
area	I:C4285457
affected	I:C4285457
by	I:C4285457
fibrosis	I:C4285457
(	O
TIF	O
)	O
and	O
glomerulosclerosis	B:C0178664
were	O
measured	O
at	O
baseline	O
and	O
after	O
24	O
months	O
.	O

The	O
baseline	O
eGFR	B:C0017654
was	O
80±6	O
in	O
the	O
placebo	O
and	O
86±6	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
in	O
the	O
eplerenone	O
group	I:C1257890
;	O
at	O
24	O
months	O
it	O
was	O
66±8	O
and	O
81±7	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
(	O
P=0.33	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-	O
18	O
to	O
33	O
at	O
baseline	O
,	O
and	O
-	O
11	O
to	O
40	O
after	O
24	O
months	O
)	O
.	O

The	O
baseline	O
eGFR	O
was	O
80±6	O
in	O
the	O
placebo	B:C1257890
and	O
86±6	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
in	O
the	O
eplerenone	O
group	I:C1257890
;	O
at	O
24	O
months	O
it	O
was	O
66±8	O
and	O
81±7	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
(	O
P=0.33	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-	O
18	O
to	O
33	O
at	O
baseline	O
,	O
and	O
-	O
11	O
to	O
40	O
after	O
24	O
months	O
)	O
.	O

The	O
baseline	O
eGFR	O
was	O
80±6	O
in	O
the	O
placebo	O
and	O
86±6	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
in	O
the	O
eplerenone	B:C1257890
group	I:C1257890
;	O
at	O
24	O
months	O
it	O
was	O
66±8	O
and	O
81±7	O
ml	O
/	O
min	O
per	O
1.73	O
m	O
(	O
2	O
)	O
,	O
respectively	O
(	O
P=0.33	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-	O
18	O
to	O
33	O
at	O
baseline	O
,	O
and	O
-	O
11	O
to	O
40	O
after	O
24	O
months	O
)	O
.	O

The	O
albumin	B:C1318293
-	I:C1318293
to	I:C1318293
-	I:C1318293
creatinine	I:C1318293
ratio	I:C1318293
was	O
110±74	O
in	O
the	O
placebo	O
,	O
and	O
265±140	O
mg/g	O
in	O
the	O
eplerenone	O
group	I:C1257890
;	O
and	O
after	O
24	O
months	O
it	O
was	O
276±140	O
and	O
228±88	O
mg/g	O
,	O
respectively	O
(	O
P=0.15	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-	O
283	O
to	O
593	O
,	O
and	O
-	O
485	O
to	O
391	O
,	O
respectively	O
)	O
.	O

The	O
albumin	O
-	I:C1318293
to	I:C1318293
-	I:C1318293
creatinine	I:C1318293
ratio	I:C1318293
was	O
110±74	O
in	O
the	O
placebo	B:C1257890
,	O
and	O
265±140	O
mg/g	O
in	O
the	O
eplerenone	O
group	I:C1257890
;	O
and	O
after	O
24	O
months	O
it	O
was	O
276±140	O
and	O
228±88	O
mg/g	O
,	O
respectively	O
(	O
P=0.15	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-	O
283	O
to	O
593	O
,	O
and	O
-	O
485	O
to	O
391	O
,	O
respectively	O
)	O
.	O

The	O
albumin	O
-	I:C1318293
to	I:C1318293
-	I:C1318293
creatinine	I:C1318293
ratio	I:C1318293
was	O
110±74	O
in	O
the	O
placebo	O
,	O
and	O
265±140	O
mg/g	O
in	O
the	O
eplerenone	B:C1257890
group	I:C1257890
;	O
and	O
after	O
24	O
months	O
it	O
was	O
276±140	O
and	O
228±88	O
mg/g	O
,	O
respectively	O
(	O
P=0.15	O
;	O
95	O
%	O
confidence	O
intervals	O
,	O
-	O
283	O
to	O
593	O
,	O
and	O
-	O
485	O
to	O
391	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
placebo	B:C0032042
exhibited	O
a	O
greater	O
TIF	O
,	O
glomerulosclerosis	O
,	O
and	O
urinary	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

In	O
addition	O
,	O
the	O
placebo	O
exhibited	O
a	O
greater	O
TIF	B:C4285457
,	O
glomerulosclerosis	O
,	O
and	O
urinary	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

In	O
addition	O
,	O
the	O
placebo	O
exhibited	O
a	O
greater	O
TIF	O
,	O
glomerulosclerosis	B:C0178664
,	O
and	O
urinary	O
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

In	O
addition	O
,	O
the	O
placebo	O
exhibited	O
a	O
greater	O
TIF	O
,	O
glomerulosclerosis	O
,	O
and	O
urinary	B:C0042036
heat	O
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

In	O
addition	O
,	O
the	O
placebo	O
exhibited	O
a	O
greater	O
TIF	O
,	O
glomerulosclerosis	O
,	O
and	O
urinary	O
heat	B:C0256926
shock	I:C0256926
protein	I:C0256926
72	I:C0256926
compared	O
with	O
the	O
eplerenone	O
group	O
.	O

Although	O
this	O
study	B:C2603343
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long	O
-	O
term	O
eplerenone	O
administration	O
attenuates	O
the	O
progression	O
of	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
mineralocorticoid	O
receptor	I:C3540676
blockade	I:C3540676
in	O
this	O
pediatric	O
population	I:C1257890
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long	O
-	O
term	O
eplerenone	B:C0961485
administration	O
attenuates	O
the	O
progression	O
of	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
mineralocorticoid	O
receptor	I:C3540676
blockade	I:C3540676
in	O
this	O
pediatric	O
population	I:C1257890
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long	O
-	O
term	O
eplerenone	O
administration	B:C1533734
attenuates	O
the	O
progression	O
of	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
mineralocorticoid	O
receptor	I:C3540676
blockade	I:C3540676
in	O
this	O
pediatric	O
population	I:C1257890
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long	O
-	O
term	O
eplerenone	O
administration	O
attenuates	O
the	O
progression	O
of	O
chronic	B:C0403592
allograft	I:C0403592
nephropathy	I:C0403592
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
mineralocorticoid	O
receptor	I:C3540676
blockade	I:C3540676
in	O
this	O
pediatric	O
population	I:C1257890
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long	O
-	O
term	O
eplerenone	O
administration	O
attenuates	O
the	O
progression	O
of	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
mineralocorticoid	B:C3540676
receptor	I:C3540676
blockade	I:C3540676
in	O
this	O
pediatric	O
population	I:C1257890
.	O

Although	O
this	O
study	O
was	O
underpowered	O
to	O
provide	O
definitive	O
evidence	O
that	O
long	O
-	O
term	O
eplerenone	O
administration	O
attenuates	O
the	O
progression	O
of	O
chronic	O
allograft	I:C0403592
nephropathy	I:C0403592
in	O
pediatric	O
transplant	O
patients	O
,	O
it	O
encourages	O
testing	O
the	O
potential	O
benefit	O
of	O
mineralocorticoid	O
receptor	I:C3540676
blockade	I:C3540676
in	O
this	O
pediatric	B:C1257890
population	I:C1257890
.	O

